Diamonds and Dogs


Bluebird Bio (BLUE) is flying high. The biotech stock is up 10.1% on news their rival, Novartis (NVS) received approval from the FDA for their therapy to reprogram immune cells to attack cancer cells. Bluebird Bio has a similar therapy that does not compete with the Novartis therapy, but uses the same technology. Celgene (CELG) is up 3% as they are partnering with Bluebird Bio.

Going from bad to worse.  While the other big banks are making new highs, Wells Fargo (WFC) is going in the opposite direction, down a percent today and down 13% in the last six months as an expanded third-party review of their retail banking business showed an additional 1.4 million of unauthorized accounts were opened expanding the total to 3.5 million unauthorized consumer and small business accounts opened to meet quotas. Sounds like management is out of control at Wells Fargo.

Diamonds and Dogs market commentary is a journal of daily observations on anything that happens to be of interest to our author. Obviously, our primary focus is the stock market and world economic events, but for this page we have no defined topics. We want this page to be dedicated to the interests, concerns, and possibly to the financial gain of our clients and friends. All comments contained herein are for informational purposes only, and should not be considered as a solicitation to buy or sell any security. The firm does not guarantee the accuracy or completeness of the information or make any warranties regarding results from it's usage.